about
Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinomaBiological activity of the thyroid TRK-T3 oncogene requires signalling through ShcImatinib mesylate in chordomaIntegrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomasAnalysis of SHP-1-mediated down-regulation of the TRK-T3 oncoprotein identifies Trk-fused gene (TFG) as a novel SHP-1-interacting protein.Role of STAT3 in in vitro transformation triggered by TRK oncogenes.Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins.A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.Rearrangements of NTRK1 gene in papillary thyroid carcinoma.The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screeningOncogenic rearrangements of the NTRK1/NGF receptor.Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.RET inhibition: implications in cancer therapy.miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy.S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma.TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells.Multikinase inhibitors in thyroid cancer.Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angioThe TFG protein, involved in oncogenic rearrangements, interacts with TANK and NEMO, two proteins involved in the NF-kappaB pathway.PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma.Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells.Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.Are two better than one? A novel double-mutant KIT in GIST that responds to ImatinibRefined localization of the human TPR gene to chromosome 1q25 by in situ hybridization.Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.Biological activity of the thyroid TRK-T3 oncogene requires signalling through ShcTRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.Functional characterization of NTRK1 mutations identified in melanoma.Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation.The M581V mutation, associated with a mild form of congenital insensitivity to pain with anhidrosis, causes partial inactivation of the NTRK1 receptor.Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.Loss of function effect of RET mutations causing Hirschsprung disease.Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.
P50
Q24309898-18D2A85B-909D-440C-BAF6-E0B8C3721F9DQ24648398-D0F50858-6EB1-4991-9DE3-8F084B4DE8CFQ28282621-4F6B4F28-02EA-4C63-99EC-A74A30885372Q28475549-E7954C1B-57A9-4486-B08F-FC9471766084Q33292197-DF6DFEA1-81BF-4B72-985B-4A7AD1C12E79Q33538057-509A01B8-6D30-4BAB-9D40-55A53D5AED9BQ33538057-F56DFF84-814A-4B77-B0C2-C219BE2B998AQ34078370-80565B3C-4219-4E24-8B2A-EB6BDCFBC05BQ34102992-15EBCF66-0E65-4059-8B6C-97113836A0C6Q34177211-A9FDFA6B-CB4B-4AB0-9F27-2DECF55C3A2FQ34331384-A2422339-556A-42FC-BFEE-A78E5DB2D0A2Q35010947-78C5143B-B57C-4AF7-980B-44317A77965DQ35215959-334109BC-D3C6-4B0C-B01B-C8012DD158C9Q35797331-DAE9D91A-151F-492D-AE72-F21535271D70Q36293836-383EF542-FF20-408E-8541-EF86269666ABQ36414422-986E72DD-C1E7-4ADC-BF4E-D574446E5E84Q38086590-C24E6CC9-6FDE-4A43-AB3E-22D38BA45C6AQ38395979-DFF8A858-4BBB-4F63-A0EA-238673D627EAQ39014857-F6BDAEA1-B87C-48F1-9473-52A3568A082FQ39113324-7FF271C6-422E-4525-800E-05F71A35DABEQ39588375-7DD361EC-6346-4FDE-9B5B-C96B59CE71C8Q39737306-6DDB7A85-4511-4819-A8C6-94D33C390C6DQ39833233-311D3E79-51EB-4031-A55D-D127A3490B3EQ40082333-F96F822B-E17F-4D25-AA38-3B9A2F1BAD11Q40302096-6B27B1D9-0386-4097-B0FC-9A80972220AEQ40351643-AC5CF44A-A68A-463D-B597-133F9F38D675Q40590667-FCCE0164-4619-4E8A-AA85-4A8DDC14FFE1Q40701711-364346FC-ADA5-432A-8CC4-367CADE10CEBQ40814248-221FC5C5-D4C7-4AE9-B6A9-CA751D057F57Q41134178-D5472256-BB48-42FD-9DE6-1B712A02B532Q41439522-1F01970E-777A-4767-9A8F-CCB2668F24FAQ41496425-ADCB546C-93D8-47F1-B6FD-B41C3FD5B259Q42181442-FA827D57-B64C-4E96-9C73-90F01BF7CD21Q42434702-81EA01A6-5092-452E-8048-67A14D7FE619Q42800430-F9655238-D313-4F4E-83E8-B6DDCFA63A17Q42800660-2CB75DE3-802D-4847-868A-1CBDC06C5369Q42805238-24D33632-57DC-4B92-8C5E-86B9423609F5Q42808822-8313AD24-7225-424C-AD33-9EAEC92F330DQ42809101-FC8C6775-5B71-4932-A96F-6E26BA8764C0Q42828135-BF31F032-A1E3-4690-91DA-66987120D53B
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Angela Greco
@ast
Angela Greco
@en
Angela Greco
@es
Angela Greco
@nl
type
label
Angela Greco
@ast
Angela Greco
@en
Angela Greco
@es
Angela Greco
@nl
prefLabel
Angela Greco
@ast
Angela Greco
@en
Angela Greco
@es
Angela Greco
@nl
P106
P1153
7201390180
P21
P31
P496
0000-0003-2994-0349